News | Novartis novartis.com

Novartis erzielte im Jahr 2025 eine Umsatzsteigerung im hohen einstelligen Prozentbereich, eine Kerngewinnmarge von 40% sowie weitere Fortschritte in der Pipeli...

novartis.com·1d

Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025

novartis.com·1d

How Novartis is helping to eliminate leprosy

novartis.com·1d

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

novartis.com·2w

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

novartis.com·3w

Novartis and US government reach agreement on lowering drug prices in the US

novartis.com·6w

Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses

novartis.com·8w

1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years

novartis.com·8w

Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS

novartis.com·10w

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

novartis.com·10w

Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets

novartis.com·11w

Novartis announces plans to build flagship manufacturing hub in North Carolina

novartis.com·11w

Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance

novartis.com·12w

Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance

novartis.com·14w

Novartis verzeichnet im dritten Quartal solide Steigerungen beim Umsatz und operativen Kernergebnis sowie starke Fortschritte in der Pipeline; Prognose für das Geschäftsjahr 2025 bestätigt

novartis.com·14w

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

novartis.com·14w

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

novartis.com·18w

Bringing breakthroughs to more patients

novartis.com·18w

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

novartis.com·25w

Novartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company

novartis.com·29w

Loading...Loading more...